Academic Journal
Steroidal alkaloid H89712 ameliorates neuroinflammation and memory deficits: Enhancing cerebral oxidative phosphorylation in APP/PS1 mice.
| Τίτλος: | Steroidal alkaloid H89712 ameliorates neuroinflammation and memory deficits: Enhancing cerebral oxidative phosphorylation in APP/PS1 mice. |
|---|---|
| Συγγραφείς: | Jiang L; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China; Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, 410008, Hunan, China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, 410008, Hunan, China; National Clinical Research Center for Geriatric Disorders, Changsha, 410008, Hunan, China., Zhang Z; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China; Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, 410008, Hunan, China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, 410008, Hunan, China; National Clinical Research Center for Geriatric Disorders, Changsha, 410008, Hunan, China., Luo X; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China; Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, 410008, Hunan, China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, 410008, Hunan, China; National Clinical Research Center for Geriatric Disorders, Changsha, 410008, Hunan, China., Wu H; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China; Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, 410008, Hunan, China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, 410008, Hunan, China; National Clinical Research Center for Geriatric Disorders, Changsha, 410008, Hunan, China., Huang Z; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China; Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, 410008, Hunan, China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, 410008, Hunan, China; National Clinical Research Center for Geriatric Disorders, Changsha, 410008, Hunan, China., Wu W; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China; Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, 410008, Hunan, China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, 410008, Hunan, China; National Clinical Research Center for Geriatric Disorders, Changsha, 410008, Hunan, China., Xu S; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China; Phase I Clinical Trial Center, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China., Pan J; Clinical Research Laboratory, the Second Affiliated Hospital of University of South China, Hengyang, 421001, Hunan, China. Electronic address: 13787702128@139.com., Tan Z; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China; Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, 410008, Hunan, China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, 410008, Hunan, China; National Clinical Research Center for Geriatric Disorders, Changsha, 410008, Hunan, China. Electronic address: 803119@csu.edu.cn. |
| Πηγή: | Life sciences [Life Sci] 2026 Oct 01; Vol. 402, pp. 124583. Date of Electronic Publication: 2026 Jul 08. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0375521 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0631 (Electronic) Linking ISSN: 00243205 NLM ISO Abbreviation: Life Sci Subsets: MEDLINE |
| Imprint Name(s): | Publication: <2008->: Amsterdam : Elsevier Original Publication: Oxford; Elmsford, N. Y. [etc.] Pergamon Press. |
| Ιατρικοί όροι (MeSH): | Memory Disorders*/drug therapy , Memory Disorders*/metabolism , Oxidative Phosphorylation*/drug effects , Neuroinflammatory Diseases*/drug therapy , Neuroinflammatory Diseases*/metabolism , Alkaloids*/pharmacology , Alzheimer Disease*/drug therapy , Alzheimer Disease*/metabolism , Steroids*/pharmacology, Amyloid beta-Protein Precursor/genetics ; Hippocampus/drug effects ; Hippocampus/metabolism ; Neuroprotective Agents/pharmacology ; Maze Learning/drug effects ; Presenilin-1/genetics ; Apoptosis/drug effects ; Animals ; Mice ; Male ; Mice, Transgenic ; Disease Models, Animal |
| Περίληψη: | Aims: Alzheimer's disease (AD) poses a major health challenge with limited therapeutic options. This study aimed to investigate the anti-AD potential and underlying mechanism of a novel steroidal alkaloid, H89. Materials and Methods: In vitro, Aβ Key Findings: H89 (10 and 50 nM) significantly protected HT-22 cells against Aβ Significance: H89 exerts neuroprotective effects by enhancing mitochondrial oxidative phosphorylation and brain energy supply, concurrently suppressing neuroinflammation, oxidative stress, and neuronal apoptosis, suggesting its potential as a therapeutic candidate for AD. (Copyright © 2026 Elsevier Inc. All rights reserved.) |
| Competing Interests: | Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. |
| Contributed Indexing: | Keywords: Alzheimer's disease; H89712; Mitochondrial dysfunction; Neuroinflammation; Oxidative phosphorylation; Steroidal alkaloid |
| Substance Nomenclature: | 0 (Alkaloids) 0 (Amyloid beta-Protein Precursor) 0 (Neuroprotective Agents) 0 (Steroids) 0 (Presenilin-1) |
| Entry Date(s): | Date Created: 20260707 Date Completed: 20260811 Latest Revision: 20260811 |
| Update Code: | 20260812 |
| DOI: | 10.1016/j.lfs.2026.124583 |
| PMID: | 42413720 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1879-0631 |
|---|---|
| DOI: | 10.1016/j.lfs.2026.124583 |